Thu, Aug 28, 2014, 4:02 AM EDT - U.S. Markets open in 5 hrs 28 mins

Recent

% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

  • martin.prochazka1 martin.prochazka1 Jun 11, 2009 3:40 PM Flag

    ARDM today 40%! Tomorrow again! Check it!! $1 next week!!

     

    Just to say ARDM target shows me at EW counts the value 2.87 - 3.05 before approval. The pending date is 15 July.
    This stock is going to do well the next few weeks :)

    ARDM:
    "In August 2006, we sold all of our assets related to the Intraject needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to Zogenix, Inc., a private company. Zogenix is responsible for further development and commercialization efforts of Intraject (now rebranded under the name DoseProtm). We received a $4.0 million initial payment from Zogenix, and we will be entitled to a milestone payment upon initial commercialization, and royalty payments upon any commercialization of products in the U.S. and other countries, including the European Union, that may be developed and sold using the DosePro technology. In December 2007, Zogenix submitted a New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for the migraine drug sumatriptan using the needle-free injector DosePro ("Sumaveltm DosePro"). The NDA was accepted for filing by the FDA in March 2008. The same month, Zogenix entered into a license agreement to grant exclusive rights in the European Union to Desitin Pharmaceuticals, GmbH to develop and commercialize Sumavel DosePro in the European Union. On October 31, 2008, Zogenix received a Complete Response Letter from the FDA on its NDA. On February 18, 2009, Zogenix disclosed that the Complete Response letter from the FDA cited the need for a single additional in vitro test to be conducted and that Zogenix recently submitted the requested information to the FDA. The FDA accepted this resubmission as a complete response, providing the new Prescription Drug User Fee Act (PDUFA) review date of July 15, 2009. Zogenix stated that it is their intention to launch Sumavel DosePro following FDA approval in the second half of 2009.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
VICL
1.26-0.01(-0.79%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TubeMogul, Inc.
NasdaqGSWed, Aug 27, 2014 4:00 PM EDT
Burger King Worldwide, Inc.
NYSEWed, Aug 27, 2014 4:00 PM EDT